340 related articles for article (PubMed ID: 31937920)
1. Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Siva S; Udovicich C; Tran B; Zargar H; Murphy DG; Hofman MS
Nat Rev Urol; 2020 Feb; 17(2):107-118. PubMed ID: 31937920
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
4. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
[TBL] [Abstract][Full Text] [Related]
5. Utility of
Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific membrane antigen for prostate cancer theranostics: from imaging to targeted therapy.
Arsenault F; Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2018 Sep; 12(3):359-365. PubMed ID: 29939893
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer.
Barrio M; Fendler WP; Czernin J; Herrmann K
Expert Rev Mol Diagn; 2016 Nov; 16(11):1177-1188. PubMed ID: 27679869
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
9. PET imaging in urology: a rapidly growing successful collaboration.
Farolfi A; Koschel S; Murphy DG; Fanti S
Curr Opin Urol; 2020 Sep; 30(5):623-627. PubMed ID: 32701721
[TBL] [Abstract][Full Text] [Related]
10.
von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
[TBL] [Abstract][Full Text] [Related]
11. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
12. Imaging of Prostate-Specific Membrane Antigen with Small-Molecule PET Radiotracers: From the Bench to Advanced Clinical Applications.
Rowe SP; Gorin MA; Pomper MG
Annu Rev Med; 2019 Jan; 70():461-477. PubMed ID: 30691373
[TBL] [Abstract][Full Text] [Related]
13. A prospective randomized multicentre study of the impact of gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging for staging high-risk prostate cancer prior to curative-intent surgery or radiotherapy (proPSMA study): clinical trial protocol.
Hofman MS; Murphy DG; Williams SG; Nzenza T; Herschtal A; Lourenco RA; Bailey DL; Budd R; Hicks RJ; Francis RJ; Lawrentschuk N
BJU Int; 2018 Nov; 122(5):783-793. PubMed ID: 29726071
[TBL] [Abstract][Full Text] [Related]
14. Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?
Pozzessere C; Bassanelli M; Ceribelli A; Rasul S; Li S; Prior JO; Cicone F
Curr Urol Rep; 2019 Oct; 20(11):68. PubMed ID: 31605269
[TBL] [Abstract][Full Text] [Related]
15. Current and Emerging Clinical Applications of PSMA PET Diagnostic Imaging for Prostate Cancer.
Farolfi A; Calderoni L; Mattana F; Mei R; Telo S; Fanti S; Castellucci P
J Nucl Med; 2021 May; 62(5):596-604. PubMed ID: 33712536
[TBL] [Abstract][Full Text] [Related]
16. The role of prostate-specific membrane antigen PET/computed tomography in primary staging of prostate cancer.
Koschel S; Murphy DG; Hofman MS; Wong LM
Curr Opin Urol; 2019 Nov; 29(6):569-577. PubMed ID: 31567440
[TBL] [Abstract][Full Text] [Related]
17. Current application and future perspectives of prostate specific membrane antigen PET imaging in prostate cancer.
Ceci F; Castellucci P; Fanti S
Q J Nucl Med Mol Imaging; 2019 Mar; 63(1):7-18. PubMed ID: 29521482
[TBL] [Abstract][Full Text] [Related]
18. The Role of Positron Emission Tomography With (68)Gallium (Ga)-Labeled Prostate-specific Membrane Antigen (PSMA) in the Management of Patients With Organ-confined and Locally Advanced Prostate Cancer Prior to Radical Treatment and After Radical Prostatectomy.
Rai BP; Baum RP; Patel A; Hughes R; Alonzi R; Lane T; Adshead J; Vasdev N
Urology; 2016 Sep; 95():11-5. PubMed ID: 26790588
[TBL] [Abstract][Full Text] [Related]
19. Advances in Urologic Imaging: Prostate-Specific Membrane Antigen Ligand PET Imaging.
Hofman MS; Iravani A; Nzenza T; Murphy DG
Urol Clin North Am; 2018 Aug; 45(3):503-524. PubMed ID: 30031469
[TBL] [Abstract][Full Text] [Related]
20. PET/CT imaging of prostate cancer in the era of small molecule prostate specific membrane antigen targeted tracers.
Vrachimis A; Ferentinos K; Demetriou E; Ioannides C; Zamboglou N
Hell J Nucl Med; 2020; 23(3):339-345. PubMed ID: 33306762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
